This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Medical Practice  • Conflict of Interest  • Law and Medicine  • Statistics and Research Methods  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Mike Mitka

JAMA. 2009;302(6):619.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Senators who previously called for increased transparency in the financial relationships between physicians and manufacturers of drugs, devices, and biologics are now pressing for such openness among researchers who receive grants from the National Institutes of Health (NIH).

In a July 7 letter, Sen Chuck Grassley (R, Iowa) and Sen Herb Kohl (D, Wis) said the NIH should require its grantees to report outside income to the nearest $1000 and oblige universities to complete plans to manage potential conflicts of interest (http://grassley.senate.gov/news/Article.cfm?customel_dataPageID_1502=21709). In addition, information on both actions should be posted on the NIH's Web site, the letter said.

The letter, which was part of an NIH request for public comment on proposed changes in its disclosure policy, cited several examples of NIH-funded investigators conducting drug and device research who also had financial relationships with the companies that produced the health care products being studied. "It . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?